Mr Wayne Tan is a serial entrepreneur, highly experienced business developer, and versatile business innovator with over 28 years of experience in high-profile commercial development. He is currently the CEO of Peking University Biologics, one of the world’s single largest biologics CDMO manufacturing sites in China, with over 30 years of experience in biologics development and manufacturing. One of Mr Tan’s key roles is to expand Peking University Biologics business paradigm into the global biologics market, offering professional “One-Stop” biologics CDMO services to the world. These include full support to the Chinese biotech to expand their business and opportunity to Japan, USA, and Europe without necessity to set up their team in overseas.

Prior to Peking University Biologics, he was the CEO (APAC) of Clinipace Worldwide, a global CRO, focusing in supporting international pharmaceutical companies (eg. Roche, Novartis, Takeda, etc.) for regulatory affairs, drug development and clinical trial, etc.

Presently, Mr Tan is also serving at three well-known organisations and governmental institutions and plays senior roles to develop and promote the biomedical industry. He serves as the Executive Director in HK Bio-Med Innotech Association (HKBMIA), a non-profit organisation, Shenzhen Government’s “Key Cooperation Project Partners” and a member of the Cross-strait Bio-Med Innotech Alliance (China, Hong Kong, Macau & Taiwan). HKBMIA is committed to establishing an innovative and international biomedical technology platform in Hong Kong. Mr Tan involved in organising 12 main services in HKBMIA, offering “One-Stop” Biotech-ECO-System to the public. These include fund-raising, IP protection, clinical development, project valuation, scientific advisory, commercialisation, etc., and also inviting international professionals (e.g. HSBC, KPMG, IQVIA, etc.) to offer professional advice to the biotech sector to enhance communication and co-operation amongst the biomedical innovation technology industry, research institute, and government organisations.

Mr Tan is also officially appointed by Shenzhen Pingshan District Government as “Biotech Advisor” of Pingshan District Science and Technology Innovation Bureau as well as “Official Representative” of Pingshan District Science and Technology Innovation Bureau in Hong Kong, responsible for making an effort to develop the biomedical industry with the government and to develop and implement the Guangdong-Hong Kong-Macao Greater Bay Area Plan.

(Updated as at Aug 2021)